Balance Sheet: Assets

The balance sheet provides creditors, investors, and analysts with information on company resources (assets) and its sources of capital (its equity and liabilities). It normally also provides information about the future earnings capacity of a company assets as well as an indication of cash flows that may come from receivables and inventories.

Assets are resources controlled by the company as a result of past events and from which future economic benefits are expected to flow to the entity.

Edwards Lifesciences Corp., consolidated balance sheet: assets

US$ in thousands

	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017
Cash and cash equivalents	862,800)	1,183,200)	1,179,100)	714,100)	818,300)
Short-term investments	604,000)	219,400)	337,800)	242,400)	519,200)
Accounts receivable, net of allowances	582,200)	514,600)	543,600)	456,900)	421,600)
Other receivables	82,700)	88,200)	55,500)	80,400)	40,600)
Inventories	726,700)	802,300)	640,900)	607,000)	554,900)
Prepaid expenses	85,200)	75,100)	59,100)	54,300)	60,600)
Other current assets	237,100)	208,200)	168,000)	131,800)	116,900)
Current assets	3,180,700)	3,091,000)	2,984,000)	2,286,900)	2,532,100)
Long-term investments	1,834,200)	801,600)	585,500)	506,300)	567,000)
Property, plant, and equipment, net	1,546,600)	1,395,200)	1,060,300)	867,500)	679,700)
Operating lease right-of-use assets	92,100)	94,200)	80,100)	—)	—)
Goodwill	1,167,900)	1,173,200)	1,167,700)	1,112,200)	1,126,500)
Other intangible assets, net	323,600)	331,400)	336,500)	343,200)	468,000)
Deferred income taxes	246,700)	230,900)	172,200)	174,000)	213,600)
Other assets	110,800)	119,600)	101,800)	33,600)	108,900)
Long-term assets	5,321,900)	4,146,100)	3,504,100)	3,036,800)	3,163,700)
Total assets	8,502,600)	7,237,100)	6,488,100)	5,323,700)	5,695,800)

Based on: 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31).

Assets: Selected Items

Download chart

Balance sheet item	Description	The company
Current assets	Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.	Edwards Lifesciences Corp. current assets increased from 2019 to 2020 and from 2020 to 2021.
Property, plant, and equipment, net	Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.	Edwards Lifesciences Corp. property, plant, and equipment, net increased from 2019 to 2020 and from 2020 to 2021.
Long-term assets	Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.	Edwards Lifesciences Corp. long-term assets increased from 2019 to 2020 and from 2020 to 2021.
Total assets	Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.	Edwards Lifesciences Corp. total assets increased from 2019 to 2020 and from 2020 to 2021.

Current Assets: Selected Items

Download chart

Balance sheet item	Description	The company
Cash and cash equivalents	Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.	Edwards Lifesciences Corp. cash and cash equivalents increased from 2019 to 2020 but then decreased significantly from 2020 to 2021.
Short-term investments	Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.	Edwards Lifesciences Corp. short-term investments decreased from 2019 to 2020 but then increased from 2020 to 2021 exceeding 2019 level.
Accounts receivable, net of allowances	Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.	Edwards Lifesciences Corp. accounts receivable, net of allowances decreased from 2019 to 2020 but then increased from 2020 to 2021 exceeding 2019 level.
Inventories	Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.	Edwards Lifesciences Corp. inventories increased from 2019 to 2020 but then slightly decreased from 2020 to 2021.

Edwards Lifesciences Corp. (NYSE:EW)

Balance Sheet: Assets

Assets: Selected Items

Current Assets: Selected Items